LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
NERV
Minerva Neurosciences, Inc.
There isn't enough reported data to score NERV yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
NERV Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Strong |
NERV's balance sheet is currently strong, but its revenue and profitability are weak. There isn't enough data to rate its cash flow.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
NERV PE Valuation
NERV has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
NERV Forward outlook
There aren't enough analyst estimates for NERV to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over NERV on earnings quality, reporting a profit while its opponent remains loss making.
NERV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$36.57 | -$34.72 |
| Q2 2026 | -$36.74 | -2582% |
| Q1 2026 | -$37.03 | -4616% |
| Q4 2025 | -$34.67 | -18347% |
| Q3 2025 | -$1.85 | -$1.45 |
| Q2 2025 | $1.48 | +$5.88 |
| Q1 2025 | $0.82 | +$5.25 |
| Q4 2024 | $0.19 | +$4.80 |
NERV lost $36.57 per share over the past year, a bigger loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
NERV Quarterly Revenue
NERV's revenue has slid since its 2020 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2020 | 72% | N/A |
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over NERV on cash generation, producing positive trailing cash flow while its opponent burns cash.
NERV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$8.1M | -$5.2M |
| Q2 2026 | -$13.3M | -$11.3M |
| Q1 2026 | -$5.4M | -$1.4M |
| Q4 2025 | -$4.5M | +$686K |
| Q3 2025 | -$2.9M | +$1.4M |
| Q2 2025 | -$2M | +$1.9M |
| Q1 2025 | -$4.1M | +$2M |
| Q4 2024 | -$5.2M | +$824.6K |
NERV has burned cash in almost every quarter: −$31M over the past year, against −$14M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over NERV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
NERV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4.9% | -3.9M shares |
| 1 year | +894% | +67.7M shares |
| 3 years | +894% | +67.7M shares |
| 5 years | +1309% | +69.9M shares |
| Available history | +1443% | +70.4M shares |
NERV has 75M diluted shares, up 894% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
NERV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2020 | -13.6x | Net Cash |
NERV has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
NERV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.7 | Neutral |
| Stochastic | 11.3 | Oversold |
NERV's weekly RSI is 31 (neutral) and its Stochastic is 11 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
NERV PE vs Healthcare Sector
| Metric | NERV | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NERV has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over NERV on trend strength, trading above more of its moving averages.
NERV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.70 | 12% below |
| 20 week MA | $3.73 | 36% below |
| 50 week MA | $4.65 | 49% below |
| 100 week MA | $3.42 | 30% below |
| 200 week MA | $4.02 | 41% below |
NERV is in a downtrend: it's below all five of its weekly moving averages, and 41% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over NERV on returns for 2026, with the stronger performance.
NERV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $54.2 | $19.7 | -64% |
| 2021 | $19.7 | $7.72 | -61% |
| 2022 | $7.72 | $2.48 | -68% |
| 2023 | $2.48 | $6.15 | +148% |
| 2024 | $6.15 | $2.26 | -63% |
| 2025 | $2.26 | $4.19 | +85% |
| 2026 YTD | $4.19 | $2.38 | -43% |
NERV's yearly returns have swung widely, from +148% in 2023 to −68% in 2022. It's down 43% so far in 2026.